Anti-Human IL1Beta Recombinant Antibody (Canakinumab)

Customer Review

There are currently no Customer reviews or questions for TAB-021. Click the button above to contact us or submit your feedback about this product.

Citations

1. Siu, Kam-Leung, et al. "Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC." The FASEB Journal 33.8 (2019): 8865. https://doi.org/10.1096/fj.201802418R
   The article investigates the mechanism by which the SARS-CoV open reading frame 3a (ORF3a) protein activates the NLRP3 inflammasome, contributing to the cytokine storm characteristic of severe coronavirus infections. The researchers demonstrate that ORF3a uniquely activates both signals required for inflammasome activation: pro-IL-1β gene transcription through NF-κB activation, and IL-1β protein maturation through ASC-dependent caspase-1 activation. They identify a TRAF binding domain in ORF3a that enables interaction with TRAF3, which mediates K63-linked ubiquitination of ASC and promotes ASC speck formation. Unlike other viral inflammasome activators, ORF3a's ability to stimulate inflammasome activation is independent of its ion channel activity but requires TRAF3, NLRP3, and ASC.
   Creative Biolabs provided Canakinumab, a therapeutic antibody that blocks IL-1β, which was used to assess the impact of IL-1β inhibition on SARS-CoV replication. The researchers demonstrated that treatment with this antibody mildly increased viral replication, suggesting that inflammasome activation has a weak suppressive effect on SARS-CoV. This finding helps clarify the dual role of inflammasome activation in coronavirus infections - serving both antiviral functions and potentially contributing to pathological inflammation - providing valuable insights for therapeutic strategies targeting coronavirus-induced inflammatory responses.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-021, RRID: AB_3111754)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Siu, Kam-Leung, et al. "Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC." The FASEB Journal (2019): fj-201802418R.

Biosimilar Overview

Please refer to Canakinumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Canakinumab.

Related Diseases

Rheumatoid Arthritis

Maturity Onset Diabetes of the Young

Related Signaling Pathways

TNF Signaling Pathway

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Canakinumab"

Afuco™ Anti-IL1B ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-021)

This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to Human IL1 beta. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249)

Canakinumab is a recombinant anti-human IL-1β monoclonal antibody marketed for treating Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). The DrugMonitor™ Anti-Canakinumab Antibody (VS-1224-YC249) is an anti-drug antibody (ADA) against Canakinumab. This drug-based antibody is raised in mice immunized with the Canakinumab. The anti-Canakinumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Canakinumab in samples.

See other products for "IL1B"

Select a product category from the dropdown menu below to view related products.